IMPURITIES AVAILABLE FOR 'Erlotinib'
Omsynth Lifesciences Pvt. Ltd. is one of the leading manufacturer and exporter of Erlotinib. Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by blocking the activity of EGFR, a protein that promotes the growth of cancer cells. Erlotinib is particularly effective in patients with EGFR mutations. It helps slow tumor progression and can improve survival in eligible patients. Common side effects include rash, diarrhea, loss of appetite, and fatigue. Monitoring for skin reactions and liver function is important during treatment. Buy high quality Erlotinib from Omsynth Lifesciences.
Total Products : 25 (Page 1 of 2)| CAT No. : | OM_3626 |
| CAS No : | 950596-59-5 |
| More Details | Enquire |
| CAT No. : | OM_13962 |
| CAS No : | 1710372-46-5 |
| More Details | Enquire |
| CAT No. : | OM_13954 |
| CAS No : | 236750-62-2 |
| More Details | Enquire |
| CAT No. : | OM_13952 |
| CAS No : | 179688-27-8 |
| More Details | Enquire |
| CAT No. : | OM_13956 |
| CAS No : | 950596-58-4 |
| More Details | Enquire |
| CAT No. : | OM_13955 |
| CAS No : | 236750-65-5 |
| More Details | Enquire |
| CAT No. : | OM_13963 |
| CAS No : | 183322-18-1 |
| More Details | Enquire |
| CAT No. : | OM_13964 |
| CAS No : | 1312937-41-9 |
| More Details | Enquire |
| CAT No. : | OM_3619 |
| CAS No : | NA |
| More Details | Enquire |
| CAT No. : | OM_3627 |
| CAS No : | 1417161-98-8 |
| More Details | Enquire |
| CAT No. : | OM_3612 |
| CAS No : | 183320-04-9 |
| More Details | Enquire |
| CAT No. : | OM_3613 |
| CAS No : | 183320-19-6 |
| More Details | Enquire |
| CAT No. : | OM_13958 |
| CAS No : | 179688-26-7 |
| More Details | Enquire |
| CAT No. : | OM_13965 |
| CAS No : | 328528-74-1 |
| More Details | Enquire |
| CAT No. : | OM_3628 |
| CAS No : | 2733154-09-9 |
| More Details | Enquire |
We Make Every Effort To Be A Responsible Business
As our expectations evolve, we seek to meet new and emerging challenges that present themselves.
